We are live on ! Find out more
OPPM

Opus Point Partners Management Portfolio holdings

AUM $55.3M
1-Year Est. Return 7.48%
This Fund
S&P 500
This Quarter Est. Return
+10.01%
1 Year Est. Return
-7.48%
3 Year Est. Return
+85.18%
5 Year Est. Return
+168.21%
10 Year Est. Return
–
AUM
$111M
AUM Growth
+$2.3M
Cap. Flow
+$4.8M
Cap. Flow %
4.31%
Top 10 Hldgs %
45.14%
Holding
70
New
3
Increased
23
Reduced
5
Closed
7
Avg Time Held Equity + Options
5.5 quarters
Top 10 Avg Time Held Equity + Options
2.9 quarters
Top 20 Avg Time Held Equity + Options
4.2 quarters
Avg Time Held Equity only
5.7 quarters
Top 10 Avg Time Held Equity only
3.1 quarters
Top 20 Avg Time Held Equity only
4.9 quarters

Top Buys

Rank Stock Value
1
BIVV
Bioverativ Inc. Common Stock
BIVV
+$648K
2
UTHR icon
United Therapeutics
UTHR
+$525K
3
ACAD icon
Acadia Pharmaceuticals
ACAD
+$509K
4
RARE icon
Ultragenyx Pharmaceutical
RARE
+$340K
5
SGEN
Seagen Inc. Common Stock
SGEN
+$316K

Top Sells

Rank Stock Value
1
KITE
Kite Pharma, Inc.
KITE
+$613K
2
MYGN icon
Myriad Genetics
MYGN
+$527K
3
SIOX
Sio Gene Therapies Inc. Common Stock
SIOX
+$404K
4
IOVA icon
Iovance Biotherapeutics
IOVA
+$220K
5
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$140K

Sector Composition

Rank Sector Weight
1 Healthcare 73.61%
2 Miscellaneous 26.05%
3 Real Estate 0.34%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
BIB icon
1
ProShares Ultra NASDAQ Biotechnology
BIB
$91.4M
$7.99M 7.17%
130,500
– –
2016 Q3
4 quarters
BMY icon
2
Bristol-Myers Squibb
BMY
$118B
$5.74M 5.15%
90,000
– –
2015 Q3
8 quarters
XBI icon
3
State Street SPDR S&P Biotech ETF
XBI
$10B
$5.63M 5.05%
65,000
– –
2016 Q2
5 quarters
ALNY icon
4
Alnylam Pharmaceuticals
ALNY
$30.4B
$5.58M 5%
47,459
-1,636
-3% -$140K
2014 Q4
11 quarters
MRK icon
5
Merck
MRK
$359B
$5.36M 4.81%
87,718
– –
2015 Q3
8 quarters
ALXN
6
CALL
DELISTED
Alexion Pharmaceuticals
ALXN
$4.91M 4.41%
35,000
– –
2017 Q1
2 quarters
IBB icon
7
iShares Biotechnology ETF
IBB
$10.5B
$4.17M 3.74%
37,500
– –
2016 Q2
5 quarters
AZN icon
8
AstraZeneca
AZN
$246B
$4.07M 3.65%
60,000
– –
2015 Q2
9 quarters
PFE icon
9
Pfizer
PFE
$162B
$4.01M 3.6%
118,364
– –
2016 Q1
6 quarters
BMY icon
10
CALL
Bristol-Myers Squibb
BMY
$118B
$2.87M 2.57%
45,000
– –
2016 Q3
4 quarters
VRTX icon
11
Vertex Pharmaceuticals
VRTX
$129B
$2.78M 2.49%
18,274
-720
-4% -$108K
2014 Q4
11 quarters
NKTR icon
12
Nektar Therapeutics
NKTR
$1.36B
$2.5M 2.25%
6,955
+475
+7% +$149K
2014 Q4
11 quarters
ALKS icon
13
Alkermes
ALKS
$6.75B
$2.45M 2.2%
48,244
+5,621
+13% +$301K
2014 Q4
11 quarters
GSK icon
14
GSK
GSK
$94B
$2.44M 2.19%
48,000
– –
2016 Q2
5 quarters
CELG
15
DELISTED
Celgene Corp
CELG
$2.36M 2.12%
16,177
+1,833
+13% +$250K
2014 Q4
11 quarters
INCY icon
16
Incyte
INCY
$22.6B
$2.35M 2.11%
20,148
+2,316
+13% +$293K
2014 Q4
11 quarters
MTD icon
17
Mettler-Toledo International
MTD
$31.3B
$2.25M 2.02%
3,594
– –
2014 Q4
11 quarters
SGEN
18
DELISTED
Seagen Inc. Common Stock
SGEN
$2.25M 2.01%
41,263
+6,170
+18% +$316K
2014 Q4
11 quarters
IONS icon
19
Ionis Pharmaceuticals
IONS
$7.26B
$2.24M 2.01%
44,183
+316
+0.7% +$16.6K
2014 Q4
11 quarters
ILMN icon
20
Illumina
ILMN
$41.8B
$2.24M 2.01%
11,550
+1,357
+13% +$253K
2014 Q4
11 quarters
AGIO icon
21
Agios Pharmaceuticals
AGIO
$1.84B
$2.23M 2%
33,347
+3,865
+13% +$232K
2015 Q3
8 quarters
AMGN icon
22
Amgen
AMGN
$226B
$2.13M 1.91%
11,406
+1,585
+16% +$281K
2014 Q4
11 quarters
RXDX
23
DELISTED
Ignyta, Inc.
RXDX
$2.11M 1.89%
170,500
– –
2017 Q2
1 quarter
BIIB icon
24
Biogen
BIIB
$33.9B
$2.09M 1.88%
6,687
+910
+16% +$269K
2014 Q4
11 quarters
REGN icon
25
Regeneron Pharmaceuticals
REGN
$78.5B
$2.04M 1.83%
4,561
+29
+0.6% +$13.8K
2014 Q4
11 quarters
1
2 3

Similar funds

KIA
Kopp Investment Advisors Bloomington, Minnesota $54.4M AUM 14.33% 1-Year Est. Return
PGA
Premia Global Advisors Coral Gables, Florida $57.9M AUM 2.91% 1-Year Est. Return
GX
Greylock XII Menlo Park, California $51.9M AUM 11.52% 1-Year Est. Return
SCG
Saban Capital Group Los Angeles, California $59.5M AUM 3.83% 1-Year Est. Return
TCMV
Technology Crossover Management VI Menlo Park, California $59.6M AUM 18.81% 1-Year Est. Return
FCM
Farmstead Capital Management Ridgewood, New Jersey $49M AUM 10.57% 1-Year Est. Return
DP
DW Partners New York $62.3M AUM 25.52% 1-Year Est. Return
SAM
Sheffield Asset Management Chicago, Illinois $48.1M AUM 12.96% 1-Year Est. Return

Opus Point Partners Management's Q3 2017 Portfolio in Review

As of Q3 2017, Opus Point Partners Management held 70 positions worth $111M, up 2.1% from $109M the previous quarter. Its ten largest holdings account for 45% of the portfolio.

Opus Point Partners Management deployed $4.8M of net new capital in Q3 2017, opening 3 new positions and adding to 23 existing holdings. Its largest new stake was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.

By sector, the portfolio is most concentrated in Healthcare at 74% of assets, up from 66% a quarter earlier, followed by Miscellaneous and Real Estate.

On the sell side, the largest reduction was Alnylam Pharmaceuticals, an estimated $140K trimmed.

  • Opus Point Partners Management's largest Q3 2017 buy was Bioverativ Inc. Common Stock: 11,056 shares worth $631K.
  • Opus Point Partners Management added most to Ultragenyx Pharmaceutical in Q3 2017, an estimated $340K increase.
  • Opus Point Partners Management's biggest Q3 2017 reduction was Alnylam Pharmaceuticals, cutting an estimated $140K.
  • Opus Point Partners Management fully exited Kite Pharma, Inc. in Q3 2017, selling an estimated $613K.
  • Opus Point Partners Management's ten largest holdings make up 45% of its $111M portfolio in Q3 2017.
  • Opus Point Partners Management opened 3 new positions and closed 7 in Q3 2017.
  • Opus Point Partners Management's portfolio value rose 2.1% quarter-over-quarter to $111M.

Based on Opus Point Partners Management's 13F filing for Q3 2017, filed 14 Nov 2017.